PolyPid Ltd. (PYPD) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

PolyPid Ltd.

PYPD

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

24M

Biotechnology

Next Earning date - 13 Nov 2024

24M

Biotechnology

Next Earning date - 13 Nov 2024

3.47USD

-0.01 ( -0.29%)

Relative Strenght

13

Volume Buzz

-12%

Earning Acce

Yes

Dist 52w H.

62%

Quote Panel

Updated October 12, 2024

1W -1.98 % 1M 0.00 % 3M -4.93 % 1Y -11.93 %

Key Metrics

Market Cap
23.61M
Shares Outstanding
6.80M
Share in Float
3.67M
Dividende
0

Earning Date
13 Nov 2024
Price Target
3.47
Average Volume
5800
Beta
1.321

Range
2.95-9.2
Industry
Biotechnology
Website
https://www.polypid.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

11.02x

P/B Ratio

5.9

Debt/Equity

0.0%

Net Margin

$-8.8

EPS

How PYPD compares to sector?

P/E Ratio

Relative Strength

PYPD

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$5M

NaN%

2025-Revenue

$2.25

-80%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Raymond James

downgrade

Previous: Not converted

2022-09-06

Now: Outperform

Guggenheim

upgrade

Previous: Not converted

2022-09-02

Now: Neutral

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-14.41
vs -15.92

Q4.22

N/A

-9.61
vs -21.32

Q1.23

N/A

-8.41
vs -18.92

Q2.23

N/A

-3.90
vs -18.32

Q3.23

N/A

-3.40
vs -14.41

Q4.23

N/A

-3.97
vs -9.61

Q1.24

N/A

-1.37
vs -8.41

Q2.24

N/A

-1.25
vs -3.90

Q3.24

N/A

-1.02
vs -3.40

Q4.24

N/A

-1.13
vs -3.97

Sales Growth

YoY

Current

Estimates

Q1.22

NA

NA vs NA

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

NA vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Return on Equity

QoQ

Q3.22

-81%

-0.81
vs -1.86

Q4.22

-111%

-1.11
vs -0.81

Q1.23

-53%

-0.53
vs -1.11

Q2.23

-70%

-0.70
vs -0.53

Q3.23

-158%

-1.58
vs -0.70

Q4.23

+303%

3.03
vs -1.58

Q1.24

-90%

-0.90
vs 3.03

Q2.24

-393%

-3.93
vs -0.90

Institutionnal Ownership

QoQ

Q3.21

19

19
vs 22

-14%

Q4.21

30

30
vs 19

58%

Q1.22

31

31
vs 30

3%

Q2.22

30

30
vs 31

-3%

Q3.22

21

21
vs 30

-30%

Q4.22

14

14
vs 21

-33%

Q1.23

10

10
vs 14

-29%

Q2.23

13

13
vs 10

30%

Earnings Growth

Latest News

PYPD

globenewswire.com

7 hours ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PYPD

globenewswire.com

7 hours ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

PYPD

globenewswire.com

7 hours ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

PYPD

globenewswire.com

7 hours ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

PYPD

seekingalpha.com

13 hours ago

PolyPid Ltd (PYPD) Q2 2024 Earnings Call Transcript

PYPD

globenewswire.com

20 hours ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

New Feature Coming Soon, Stay Tuned!

Shape

Shape